摘要:
Compounds of formula (I): wherein R1, R2, R3, R4, A and n are as defined; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
摘要:
Compounds of formula (I): wherein: when X is NR5, Y is absent or is CH2; when X is CH2, Y is absent, CH2, NR6, O, S, S(O) or S(O)2; Z is a 5- or 6-membered heterocyclyl ring; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
摘要:
Compounds of formula (I) wherein R1, R2, R3, A and n are as defined; and X is S(O)2NR4R5 or NR6S(O)2R7; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
摘要:
The invention concerns a compound of the Formula (I) wherein m is 0-2 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is halogeno, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, halogeno or (1-6C)alkyl; and R4 is (3-6C)cycloalkyl; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
摘要翻译:本发明涉及式(I)的化合物,其中m为0-2且每个R 1为基团,例如羟基,卤代,三氟甲基杂环基和杂环氧基; R 2是卤代,三氟甲基或(1-6C)烷基; R 3是氢,卤素或(1-6C)烷基; 并且R 4是(3-6C)环烷基; 或其药学上可接受的盐; 其制备方法,含有它们的药物组合物及其用于治疗由细胞因子介导的疾病或医学病症的用途。
摘要:
The invention concerns amide derivatives of Formula (Ia) wherein X is —NHCO— or —CONH—; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino and carboxy; R3 is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino and N-(1-6C)alkyl-arylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
摘要翻译:本发明涉及式(Ia)的酰胺衍生物,其中X是-NHCO-或-CONH-; m为0-3; R 1是如羟基,卤代,三氟甲基,氰基,巯基,硝基,氨基,羧基和氨基甲酰基的基团。 n为0-2; R 2是羟基,卤代,三氟甲基,氰基,巯基,硝基,氨基和羧基等基团。 R 3是氢,卤代,(1-6C)烷基或(1-6C)烷氧基; q为0-4; Q为芳基,芳氧基,芳基 - (1-6C)烷氧基,芳基氨基和N-(1-6C)烷基 - 芳基氨基; 或其药学上可接受的盐或体内可裂解的酯; 其制备方法,含有它们的药物组合物及其用于治疗由细胞因子介导的疾病或医学病症的用途。
摘要:
The invention concerns amide derivatives of Formula (Ia) wherein X is —NHCO— or —CONH—; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino and carboxy; R3 is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino and N-(1-6C)alkyl-arylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
摘要翻译:本发明涉及式(Ia)的酰胺衍生物,其中X是-NHCO-或-CONH-; m为0-3; R 1是如羟基,卤代,三氟甲基,氰基,巯基,硝基,氨基,羧基和氨基甲酰基的基团。 n为0-2; R 2是羟基,卤代,三氟甲基,氰基,巯基,硝基,氨基和羧基等基团。 R 3是氢,卤代,(1-6C)烷基或(1-6C)烷氧基; q为0-4; Q为芳基,芳氧基,芳基 - (1-6C)烷氧基,芳基氨基和N-(1-6C)烷基 - 芳基氨基; 或其药学上可接受的盐或体内可裂解的酯; 其制备方法,含有它们的药物组合物及其用于治疗由细胞因子介导的疾病或医学病症的用途。
摘要:
The invention concerns amide derivatives of the Formula (I) wherein R3 is (1-6C)alkyl or halogeno; Q is aryl or heteroaryl which optionally bears 1, 2, 3 or 4 substituents such as hydroxy, halogeno, trifluoromethyl, cyano, (1-6C)alkyl, (1-6C)alkoxy, halogeno-(1-6C)alkyl, hydroxyl-(1-6C)alkyl, di-[(1-6C)akly]amino-(1-6C)alkyl, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, aryl, aryl-(1-6C)alkoxy, heteroaryl, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; p is 0-2 and R2 is a substituent such as hydroxy and halogeno; q is 0-4; and R4 includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.